This session addressed acute promyelocytic leukemia (APL), multiple myeloma, and myelodysplastic syndromes. In particular, arsenic trioxide as a treatment for APL, one of the most highly curable types of acute myeloid leukemia, was discussed. Speakers also discussed the use of combination regimens in clinical trials for multiple myeloma treatments and therapeutic agents in the treatment of myelodysplastic syndromes.